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AbstrACt
Objectives To explore what approaches to patient and 
public involvement (PPI) in antimicrobial medicines 
development are currently being used, what the impacts of 
PPI are on antimicrobial medicines development and what 
the barriers are to its implementation.
Design Interview study.
setting Antimicrobial medicines development research.
Participants Principal investigators known to have led 
studies involving PPI or expressed an interest in PPI.
results There is very little published work on PPI in 
antimicrobial research. Individual interviewees expressed 
scepticism about the contribution that PPI could make to 
different stages of the medicines development life cycle 
but collectively identified a range of potential benefits of 
PPI covering most stages of the medicines development 
process.
Conclusions A major issue in developing PPI in 
antimicrobial medicines development research will be 
in overcoming the view that, at best, PPI has only a 
marginal contribution to make in this area of research. 
The findings from this study, although mixed, suggest that 
well-designed PPI has an untapped potential to enhance 
antimicrobial research.
bACkgrOunD: PAtient AnD PubliC 
invOlvement in heAlth reseArCh 
There is a rapidly growing interest in patient 
and public involvement (PPI) in health 
research. INVOLVE, a UK-based advisory 
group on PPI funded by the National Insti-
tute for Health Research, defines involve-
ment as research being carried out ‘with’ 
or ‘by’ members of the public rather than 
‘to’, ‘about’ or ‘for’ them.1 This is distinct 
from either disseminating information about 
research to the public or people participating 
as subjects of the research. Examples include 
acting as joint grant holders or co-applicants 
on a research project, involvement in iden-
tifying research priorities, participating as 
members of a project advisory or steering 
group, commenting on and developing 
patient information leaflets or other research 
materials and users and/or carers themselves 
carrying out research.
Within the literature, there are ongoing 
discussions about what ‘good’ PPI looks like. 
In recent years, the term ‘co-production’ has 
gained prominence. These discussions reflect 
longer term concerns regarding the impact 
of entrenched power asymmetries between 
researchers and the public on the conduct 
and practice of involvement.2–4
PPI is advocated on several grounds—
it helps to ensure that health research is 
conducted ethically, it improves the quality of 
research design and it helps in the produc-
tion of research findings that address patient 
and public concerns. Underlying these claims 
is the assertion that PPI provides access to 
an additional source of knowledge, that is, 
experiential knowledge, which is different 
from, but equally as important as, scientific 
or professional knowledge, in carrying out 
health research.2
PPI is an international movement, with 
comparable initiatives in other countries. In 
the USA, the Patient Centered Outcomes 
Research Institute is a major source of 
research funding, focused on question gener-
ation, patient-centred clinical effectiveness 
research and broad dissemination. The 
Strategy for Patient Orientated Research in 
Canada and the Consumer and Community 
Health Research Forum (Involving People 
in Research) in Australia include consum-
er-based research and a strong consumer 
knowledge base. There are also more 
targeted interventions such as the European 
Patients’ Academy on Therapeutic Innova-
tion (EUPATI) which aims to increase the 
number of patients who are knowledgeable 
of the medicines development process and 
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therefore able to act as effective advocates and advisors in 
medicines research.
Evidence of PPI in development and research plans is 
now a requirement for many UK-based medical research 
funding bodies. In Europe, the Innovative Medicines 
Initiative places a strong emphasis on the importance of 
PPI in health research.
There has been much debate about the correct termi-
nology to use when referring to members of the public 
who are involved in designing and carrying out research. 
In this paper, we use the term ‘public contributors’ to 
cover people who may have had direct experience of an 
infection, their carers and members of the public who may 
have a more general interest in antimicrobial research.
PPi in ACute AntimiCrObiAl meDiCines reseArCh
Despite the trend towards increasing PPI in research, 
there has been apparently relatively little interest in 
public involvement in antimicrobial research. Several 
authors of this paper (DE, AG, SG, AM) were involved 
in carrying out a systematic review to identify the extent, 
quality and impact of PPI in antimicrobial drug develop-
ment research.5 No relevant studies were found, apart 
from one protocol paper with a brief mention of PPI. 
Given the rapidly growing international problem of anti-
microbial resistance, this is an important area of research 
and public concern in terms of both the need to develop 
new antimicrobials and the stewardship of existing 
antimicrobials.6
There may be a number of reasons why public involve-
ment is not prominent in antimicrobial research. One 
is that researchers involved in antimicrobial research 
may be unaware of the potential benefits of PPI. There 
is a growing evidence base for the positive impacts of 
PPI on research. This includes impacts on setting the 
research agenda, intervention development, choosing 
outcome measures, data collection, analysis of data and 
writing up and dissemination.7 8 However, there is little 
consensus on the aims, methodology and appropriate 
outcome measures for evaluating PPI. This partly reflects 
the different requirements of funders, researchers and 
public contributors in developing evidence of the bene-
fits of PPI, which in turn makes it difficult to draw firm 
conclusions.
Another barrier might be the biomedical nature of 
much of the research. It may be felt that there is less 
scope for PPI to beneficially impact on laboratory-based 
research, as opposed to more applied health services 
research. That being said, there are well-documented 
cases of public involvement in other types of medicines 
development research, perhaps the most notable being 
Epstein’s work on the development of the relation-
ship and interaction between AIDS activists and AIDS 
research.9
The example of AIDS activism is helpful but the focus 
in this paper is on acute rather than chronic infections, 
which leads us to one final, and perhaps, crucial issue, 
the temporary nature of most microbial infections. 
With many long-term conditions, there are well-estab-
lished patient groups that have advocated for the rights 
of their members to be heard in decisions about service 
provision and research that affects them. The AIDS 
activism mentioned above is one example, but groups 
representing people with mental health problems, phys-
ical disabilities and chronic conditions such as diabetes 
also spring to mind. The existence of these groups and 
networks make it easier for researchers to contact appro-
priate patients and carers and involve them in their work. 
In contrast, there are few, if any, groups, representing 
people who have experienced acute microbial infec-
tions. There are groups for conditions which may make 
people prone to recurrent infections, for example, bron-
chiectasis, chronic obstructive pulmonary disease and 
cystic fibrosis. These are important groups to be aware 
of but it should be borne in mind that people who suffer 
recurrent chronic infections due to pre-existing diseases 
may have a different experience and knowledge of their 
disease compared with those who experience a single and 
unexpected severe acute infection.
The long-term nature of some conditions also makes 
it possible for researchers to build more sustained 
relationships with these patients across the lifetime 
of a project, leading to more substantial involvement. 
Patients often experience acute bacterial infection as a 
one-off experience which is either successfully treated 
with antibiotics or may be fatal. Thus, involving patients 
in research on treating certain types of infections may 
be more problematic. What was unknown at the begin-
ning of this study was the extent to which researchers 
were able to overcome these barriers and successfully 
involve patients in antimicrobial medicines develop-
ment research.
The authors of this paper are part of a larger European 
programme of research to develop new antimicrobial 
agents (COMBACTE-MAGNET). Combating bacterial 
resistance in Europe—molecules against Gram-negative 
infections ( www. combacte. com): A consortium seeking 
new ways of treating multi-resistant bacterial infections. 
The authors have the responsibility to encourage the 
development of PPI within the COMBACTE-MAGNET 
programme and are based in Work Package 6i. It is 
therefore important to identify any relevant work on PPI 
in antimicrobial research that could be built on for the 
programme.
Our aims were therefore to identify any relevant PPI 
work taking place in antimicrobial research within the 
UK or elsewhere within the COMBACTE-MAGNET 
programme and to collect data on the approaches to PPI 
used and the impact of PPI.
reseArCh questiOns
1. What approaches to PPI in antimicrobial medicines 
development are currently being used?
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2. What are the impacts of PPI on antimicrobial medi-
cines development and what are the barriers to its 
implementation?
reseArCh Design
The majority of the data were collected by means of tele-
phone interviews. Telephone interviews were chosen 
because the potential participants were geographically 
dispersed, based in the UK, the USA, Vietnam and main-
land Europe. The numbers of people we were able to 
identify carrying out PPI in antimicrobial research were 
also relatively small. It was therefore possible to interview 
all our potential participants. Telephone interviews also 
offered a practical way to develop a more detailed under-
standing of the process and outcomes of PPI in antimicro-
bial research than would be possible using other methods 
such as a questionnaire.
Population and sample
The population was researchers involved in antimicrobial 
research within the UK and the COMBACTE-MAGNET 
programme. Potential interviewees were identified 
through our contacts within the COMBACTE-MAGNET 
programme. We also contacted INVOLVE to identify 
potential contacts but without any success. We had hoped 
that a rapid review of the literature in this area of work 
would yield some contacts.5
We had originally planned to carry out a purposive 
sample of identified contacts, but because we were only 
able to identify a small number of people to participate, 
all identified contacts were interviewed. The people 
identified were all known to our team. AM is an expert 
in this area of research and was particularly helpful in 
identifying contacts and providing introductions. This 
was significant given the lack of published literature to 
follow up or contacts from other sources. We interviewed 
nine people in total—all were male principal investiga-
tors with established research track records, five were 
based in the UK, one was based in Vietnam but the inter-
view related to work carried out in the UK, one based in 
the USA, one in Switzerland and one in the Netherlands. 
All of the researchers who had carried out work in the UK 
had experience of PPI in their research projects. It trans-
pired that the three non-UK interviewees did not have 
experience of carrying out PPI but did have opinions 
on the potential benefits of PPI. We have included their 
comments in this study because they illustrate some of the 
barriers to developing PPI in antimicrobial research.
Data collection
Interviews were conducted using a semi-structured 
approach.10 This approach allowed us to ensure that 
important topics were covered while allowing the flexi-
bility for the interviewees to raise any issues they may have 
wished to. The interviews were conducted by AG and MK 
and on average lasted 20 min. The topic guide was struc-
tured to obtain the following information:
 ► Skills or previous background in PPI
 ► Perceived value of PPI in antimicrobial medicines 
development research
 ► Where in the medicines development process PPI is 
carried out
 ► Recruitment and maintenance of PPI groups
 ► Methods of involvement
The topic guide was developed by the authors and was 
informed by our wider discussion with members of the 
Patient and Public Involvement Panel for Antimicrobial 
Drugs (PPIPAD) at regular bimonthly meetings.
In addition to the areas listed above, issues specific to 
a particular research project were pursued during the 
interviews, where they were relevant to the aims of this 
paper.
Patient involvement
This paper is part of a larger project on public involve-
ment in antimicrobial medicines development which 
includes the development of a toolkit for PPI in antimi-
crobial medicines development research. The work of 
the project is guided by members of PPIPAD. Members 
of the panel confirmed that our research questions were 
important issues to investigate. Discussions with PPIPAD 
and the project team informed the development of the 
interview schedule. PPIPAD members were not involved 
in the recruitment to this study. We will discuss with 
PPIPAD the potential for further dissemination of the 
findings from this work.
DAtA AnAlysis
The data were analysed by AG. The approach to data anal-
ysis was guided by the work of Ritchie and Spencer.11 This 
approach was taken because it was designed with research 
related to policy issues in mind and because it allows for 
themes to be developed both inductively and deductively 
from the data, that is, it was possible to explore topics 
that arose from our original research questions while 
remaining open to identifying issues and concerns related 
to PPI as identified by our interviewees.
The results are presented following the themes devel-
oped by the analysis process as follows:
 ► Responsibility for carrying out PPI
 ► Basis for public involvement
 ► Time and resource implications
 ► Recruitment of public contributors
 ► PPI activities undertaken
 ► Value added
 ► Main barriers to public involvement
results
responsibility for carrying out PPi
As stated above, three of our interviewees were interested 
in the potential contribution of PPI but had no experience 
of doing PPI. The other five interviewees were responsible 
for ensuring that PPI work was carried out in their proj-
ects in line with any commitments made in their original 
funding applications. However, in practice, responsibility 
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for PPI was usually delegated to a specific member of the 
team who was accountable for the day-to-day running of 
PPI activities.
basis for public involvement
It is common in the literature on involvement to argue 
that public contributors possess important ‘lived experi-
ence’ of a particular condition which needs to be consid-
ered, alongside other forms of knowledge, for example, 
professional and scientific, when designing research.12 
However, in antimicrobial research, we are dealing with 
acute infections which people may not have experienced 
before. This, combined with the laboratory-based nature 
of antimicrobial research, led to a questioning of the 
value of PPI by some of our interviewees. As one of our 
study participants put it, ‘I don’t think patients have any 
major role to play, honestly.’ (interview 1)
However, other interviewees did not feel that this lack 
of ‘lived experience’ of a condition disqualified public 
contributors from being able to add value to antimi-
crobial research. The ability to provide an ‘alternative 
perspective’ was seen as important. One of our inter-
viewees, for example, talked about his experience of 
involving young people in the running of trials related 
to vaccination programmes. Not only did they gain valu-
able information about the best time and place to contact 
potential participants, the young people involved also 
acted as ‘research ambassadors’, explaining the relevance 
and importance of participating in research to other 
young people and helping to create a ‘research engaged 
community’. (interview 3)
Furthermore, this interviewee felt that involvement of 
this kind
‘Empowers researchers to know that they are taking 
the views of our research subjects into account in 
terms of the importance of our research and the way 
that we do it.’
It was notable that the interviewees with some direct 
experience of PPI were generally more positive about 
the potential of PPI to aid their research than those with 
none.
time and resources
The need to allocate adequate time and resources for 
PPI was noted by interviewees. At a minimum, a budget is 
required to pay for the expenses of public contributors. It 
was also acknowledged that building relationships with a 
group of public contributors takes time but, as one inter-
viewee noted, ‘Much less time or trouble than working 
with clinical contributors.’ (interview 2)
The need for time and resources was not necessarily 
seen as a problem, particularly if justified by clear benefits 
from PPI. However, one interviewee did raise concerns 
about PPI adding, ‘an additional layer of bureaucratic 
complications.’ (interview 1)
None of the interviewees provided formal training and 
support on involvement to their public contributors, 
although most provided informal support, for example, 
by explaining a particular research project and the 
planned role of public contributors.
Nevertheless, one interviewee was sceptical of the value 
that public contributors could add without significant 
training and support because of the complexity of the 
issues raised by antimicrobial resistance and the develop-
ment of new medicines to combat this. He felt that what 
was needed was
‘… a well-educated elite representing patient groups 
who understand what we are talking about’ (inter-
view 8)
His concern was that this would be difficult to achieve 
given the short-term nature of acute infections.
recruitment of public contributors
Recruitment was seen as a major problem by several inter-
viewees because of the acute nature of most infections 
and the lack of easily identifiable patient groups to work 
with. It should be noted that this is not a problem unique 
to research in acute infections. Other forms of interac-
tion with healthcare, for example, emergency care, are 
similarly episodic.
In most examples where PPI had taken place, contribu-
tors were recruited via pre-existing involvement networks 
and contacts. As one interviewee puts it, we ‘beg, borrow 
or steal’ (interview 4). Only one of the interviewees had 
set up a public advisory group specifically for antimicro-
bial research projects—this was a relatively recent inno-
vation and was seen as a way of dealing with recruitment 
difficulties (interview 4).
Furthermore, several interviewees said that they regu-
larly worked with an informal group of public contribu-
tors across different projects. One interviewee said that 
they drew on a group of approximately 10 people to work 
with on various projects since 2010 (interview 2).
It can clearly be beneficial and time efficient to work 
with public contributors with whom the researchers had 
already established a working relationship. This may also 
be a way of coping with the difficulty of engaging with 
this group of patients as noted earlier in this paper. One 
interviewee also commented about the potential difficul-
ties caused by people dropping out of activities due to 
illness (interview 2). Having a core group to work with 
may help to minimise the impact of this kind of problem.
However, there were some concerns raised about how 
‘representative’ public contributors were. One inter-
viewee talked about most public contributors being, 
‘White, middle class types’ (interview 1) and another 
commented on the problem of bias, that is, that public 
contributors may have personal interests which they may 
wish to pursue through their involvement in research 
(interview 2).
One interviewee (interviewee 7) described the very 
valuable contribution made by one public contributor but 
was concerned that this person had a very specific interest 
and motivation to become involved in the research which 
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was not representative of the general population. This was 
particularly pronounced since other public contributors 
dropped out during the lifetime of the project leaving 
this person as the sole public contributor.
PPi activities
Despite the scepticism expressed by some as to the value 
of public involvement in antimicrobial research, inter-
viewees described a wide range of activities that public 
contributors had undertaken in their research. These 
included, advising on confidentiality issues related to 
bioinformatics, guideline development for the use of 
antimicrobials, research agenda setting, preparing ethics 
applications, reviewing interview schedules, writing lay 
summaries, selecting outcome measures and involvement 
in planning and running trials. Many of these examples 
resonate with reports on the role that PPI plays in other 
forms of research.7 8
However, there were some potential areas of PPI work 
in antimicrobial research that are not reflected in this 
broader literature. One interviewee talked about the 
importance of PPI in making judgements about the 
‘trade-off between toxicity and efficacy’ (interview 8) and 
another talked about the importance of working with 
patients and carers to design dosage regimes.
Another potential area for PPI to make a contribution, 
identified by two interviewees, is that of antimicrobial 
stewardship. Although this occurs after the drug devel-
opment process and is therefore outside the scope of this 
paper, it is worth noting that altering prescribing practice 
involves changing the behaviour of both clinicians and 
patients. Designing effective interventions to achieve this 
is likely to require the involvement of both parties.
Many of these activities described above were carried 
out face-to-face, in workshops or project meetings. Some 
activities, for example, amending information sheets, 
were often carried out via email.
value added
There was a wide range of views among our interviewees 
on the value of PPI in antimicrobial research. In some 
cases, the contribution was seen as ‘minimal’ and at best 
contributing a ‘subjective insight’. One interviewee saw 
public involvement as, ‘a lot of the time pointless’, and 
as only relevant for a ‘fraction of the time’ (interview 1).
However, another interviewee commented that, ‘PPI 
is required at all stages (of a research project)’ but that 
‘PPI has most impact at the planning stage’ as it ‘…can 
be a really good informal check that there is clarity of 
purpose’ (interview 4).
PPI was also seen as helpful in dealing with operational 
concerns as they ‘crop up’ (interview 2). One interviewee 
commented on how helpful public contributors can be in 
advising on recruitment strategies for research projects 
and ensuring the acceptability of research procedures 
and proposed interventions to research participants. For 
example, one research project involved the use of anal 
swabs. The public contributors were able to advise the 
researchers on how best to approach potential partici-
pants and discuss this issue with them in a way that mini-
mised anxiety about the process, resulting in a significant 
boost to recruitment figures (interview 6).
There was evidence of acceptance, even among those 
more sceptical about the benefits of PPI in setting the 
direction of research.
‘We should not do research because we as researchers 
think it is interesting to us and which patients think is 
never going to benefit them.’ (interview 8)
main barriers to public involvement
Some of the barriers to developing PPI in antimicrobial 
research, such as the lack of clearly identifiable patient 
groups to work with and the technical nature of some of 
the research, have already been commented on. Beyond 
this, it is clear from the interview data that we have 
collected that PPI is a new concept in the world of anti-
microbial research. Several of our interviewees had only 
recently become aware of it as a concept and were unclear 
about what it meant or how to put it into practice. There 
was also scepticism about PPI’s specific contribution to 
antimicrobial research.
For one interviewee, the main barrier to effective PPI 
is, ‘Lack of knowledge and experience of the area’. He 
commented that from his experience, the impact of PPI 
had been variable and this was related to the variable 
quality of PPI practice and facilitation. He saw this as a 
result of the PPI field being ‘relatively immature’. As he 
put it, ‘we are all learning how to do it’ (interview 4). 
These comments could apply to the general development 
of PPI in research but are particularly relevant to the area 
of antimicrobial research. It may be inferred from these 
comments that as skill and expertise are developed in 
carrying out PPI in antimicrobial research, the beneficial 
impacts will increase. This represents both a challenge 
and an opportunity for the PPI community.
DisCussiOn
Although very little has been published about PPI in anti-
microbial research, our small study suggests that, at least 
in the UK context, significant PPI work is taking place; 
however, this work is rarely written up for publication. 
This experience, although mixed, suggests that despite 
some initial scepticism, many researchers have found PPI 
beneficial to their work. As one UK-based interviewee put 
it, ‘Now that we do it I wouldn’t be without it’.
The greater uptake of PPI in the UK may simply reflect 
the fact that many research funders have made evidence 
of PPI a prerequisite for a successful application, although 
this begs the question, why have many UK funders taken 
this stance in the first place? There has been some prelim-
inary work done on different ‘cultures of involvement’ in 
different parts of Europe.13 This may be an issue that is 
worthy of further exploration and will need to be taken 
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in to account if PPI is to be implemented successfully in 
different regions of Europe.
Most of the PPI activity described by our interviewees 
related to the design and running of clinical trials. The 
contribution that PPI could make to laboratory-based 
research was absent, although PPI in this area could play 
a significant role in helping researchers to develop trans-
parency, accountability and communication of their work 
to the wider public. Evidence from other areas of basic 
research suggests that PPI can help in the development 
of research questions and outcome measures in laborato-
ry-based research.14
One of our interviewees suggested that substantial 
training would be required before public contributors 
could be involved throughout the medicines development 
process. EUPATI provides this kind of training and sees it 
as essential to enabling patients to act as effective advo-
cates. However, some writers warn that an unintended 
consequence of this training may be to create groups 
of patients who identify too closely with the concerns of 
researchers rather than providing an alternative patient 
perspective.15 In our work with PPIPAD, we have found 
that some training is necessary to enable constructive 
discussions to take place, for example, on the medicines 
development process, but we did not find that this under-
mined the ability of panel members to present their own 
view point.
Unease was also raised about the representativeness of 
potential public contributors. This is an issue which has 
been widely debated in the PPI literature.16 It is important 
to keep in mind that what is required in PPI is not statis-
tical representativeness but what may be termed ‘expe-
riential representativeness’, that is, representation of 
people with the experiential knowledge that is most rele-
vant to the work in hand. However, concerns that public 
contributors are drawn from a relatively narrow section of 
society seem well founded and are reflected in the wider 
PPI literature.
Some interviewees also seemed to view the potential 
benefits of PPI in relatively narrow terms, that is, solely 
related to experience of an infection which is transitory. 
Unlike public contributors with chronic conditions, they 
did not see public contributors in antimicrobial research 
as developing ‘expertise’ in their own illness. However, 
others saw the potential for public contributors to play a 
wider range of roles, including acting as ‘research ambas-
sadors’ and helping to create a more research receptive 
public.
Given the potential time and energy required to locate 
and involve appropriate public contributors in this area 
of work, the lack of clarity of the potential benefits of 
PPI and doubt about the ability of the public to engage 
with the issues, it is perhaps not surprising that many 
researchers in this area appear not to prioritise PPI in 
their work.
However, although individuals expressed scepti-
cism about the contribution that PPI could make to 
different stages of the medicines development life cycle, 
collectively our interviewees identified a range of poten-
tial benefits of PPI covering most stages of the medicines 
development process. Due to the lack of published work 
in this area, there has been little opportunity for the 
researchers leading PPI to share and learn from each 
other’s experiences.
strengths and limitations
Our interview sample is small and recruited via personal 
contacts. It is in no way representative of researchers in 
the antimicrobial research community. However, our aim 
was not to map PPI activity in antimicrobial research, 
but to ascertain what approaches to PPI in antimicrobial 
medicines development are currently being used, the 
impacts that these approaches are having, and barriers 
to implementing these approaches—this, we were able 
to do. While it is possible that our sample is biased and 
represents a partial view of the issues discussed, it is 
unlikely that the issues are unique to our interviewees. 
In fact, many of the issues raised are recognisable in the 
wider PPI literature.7 8
We chose to undertake the interviews via telephone. 
It is possible that the lack of body language cues and 
personal interaction may have had an effect on the quality 
of the data collected. The data we collected were not of a 
personal or sensitive nature so this may have had less of 
an impact than in some other areas of research.17
Concluding comments
A major issue in developing PPI in antimicrobial medi-
cines development research will be in overcoming the 
view that, at best, PPI has only a marginal contribution 
to make in this area of research. The findings from this 
study, although mixed, suggest that well-designed PPI has 
an untapped potential to enhance antimicrobial research. 
The difficulty is in breaking the cycle of low expectations, 
leading to low investment, leading to low impact and 
so on.18 In the UK, this cycle has begun to break down. 
This has been brought about by, among other things, 
research funders making PPI a mandatory part of grant 
applications. It may be that similar measures will need to 
be adopted in Europe and elsewhere to break this cycle, 
although the possibility that different attitudes to involve-
ment may exist in different parts of Europe may also need 
to be explored and taken into account. However, it is 
clear that significant knowledge about the benefits of PPI 
in antimicrobial research is already beginning to be accu-
mulated. Unfortunately, this practice-based knowledge is 
invisible to the wider academic community because it has 
not been published.
An important prerequisite for the future development 
of PPI in antimicrobial research will be the provision of 
clear and easily accessible guidance to researchers in 
this field on how to conduct PPI and the evidence of its 
benefits. Organisations like EUPATI have already made 
great strides in this direction. In order to tackle the issues 
raised in this article, the authors have also developed a 
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toolkit for PPI in antimicrobial medicines development 
research.19
Importantly, none of our interviewees expressed 
hostility to the concept of PPI but several remained to 
be convinced of its value. Reassuringly, it appears that 
the researchers with direct experience of PPI were also 
the most positive about its benefits. With this in mind, we 
leave the final word to one of our interviewees:
‘Go in to it (PPI) with an open mind and be prepared 
to be surprised about how valuable it will be.’
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